Managed Healthcare Executive October 18, 2024
Peter Wehrwein, Managing Editor

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years later according to Prime Therapeutics’ real-world evidence, says Ben Urick, Pharm.D., Ph.D., a health outcomes researcher for the pharmacy benefit manager.

There is almost always a gap between how participants in a clinical trial behave and what happens in the real world.

But that gap is especially wide when it comes to the glucagon-like peptide 1 (GLP-1) drugs such as semaglutide (sold as Wegovy for weight loss) and tirzepatide (sold as Zepbound for weight loss), according to Ben Urick, Pharm.D., Ph.D., a senior principal health outcomes researcher at Prime Therapeutics, a pharmacy benefit management company headquartered in the suburban Twin...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Patient / Consumer, Pharma / Biotech, Provider, Trends
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
Data show 24.3% of U.S. adults had chronic pain in past three months in 2023
GLP-1 drug coverage for obesity making inroads with large employers: Mercer
Wearable Health Tech: Innovations and Impacts on Chronic Disease Management
Advocate Health takes to Capitol Hill on hospital at home: 5 notes

Share This Article